Herman Verrelst, CEO, Biocartis [EBR: BCART]
Each year millions of people across the globe suffer from pathogen-infected diseases and diverse form of cancer. Despite tremendous advances in systemic therapies, and treatment with targeted and immunotherapies predicated on biomarker studies, Oncologists and pathologists across the world have to deal with delayed turnaround time for these biomarker reports. This delay reflects in increased time taken for treatment initiation, decreased efficacy of treatment, along with uninformed treatment decisions. This is where companies like Biocartis are moving the needle. The company can be truly credited for making molecular diagnostics the gold standard in bringing out-of-the-box solutions.
Biocartis is an innovative commercial-stage molecular diagnostics (MDx) company providing next-generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers, and the industry. Its proprietary MDxIdylla™ platform is a fully automated, real-time system that offers accurate, highly reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.
The all-in-one Idylla™ platform is highly modular and readily accommodates different labs’ throughput even as it changes over the years. It brings more insight into patient data and creates accurate Cq values per target. With a highly standardized technology forming its core, the Biocartis innovation requires only one slice of tissue or one ml of plasma per assay to produce outputs. Typically, the contamination-controlled Idylla™ solution comprises a pre-loaded disposable cartridge and other consumables, thereby reducing the handling time to two minutes per sample. The solutions’ workflow is highly simple and begins with sample and cartridge scanning followed by insertion of the cartridge. Within 90-180 minutes of thorough analysis, clinicians get direct access to console result reports.
In essence, Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. Offering assays for melanoma, colorectal, and lung cancer, the Idylla™ PCR-based molecular testing system offers accurate results in a minimum amount of time. The robust platform is embedded with sophisticated technologies that allow healthcare professionals to update the solution according to market needs. Be it lung cancer, colorectal cancer, melanoma, or immuno-oncology, Idylla™ provides fast, reliable, and actionable results that enable caregivers to bridge the gap in the delay associated with obtaining molecular testing for cancer expeditiously.
Biocartis works closely with its pharma partners to facilitate accelerated access to treatment by ensuring companion diagnostic testing readiness in the relevant markets at the time of launch. Its dedicated and immensely experienced Companion Diagnostics (CDx) team facilitates decentralized molecular testing to accelerate patient access to precision medicine. With CE-marked and approvals in numerous countries worldwide, the team with the IdyllaTM platform as well as most assays is helping clients to navigate the regulatory landscape in key global territories. In that regard, Biocartis is continuously working on the production of safe, effective, and high-quality products which are in harmony with applicable regulations. “2020 was an extraordinary year, to say the least. The pandemic deprioritized and disrupted cancer care globally. Patient access to hospitals was significantly restricted throughout almost the entire year and customer prospection was severely hampered. Nevertheless, we showed resilience and delivered on our pre-pandemic outlook. The versatility of Idylla™ allowed the rapid rollout of a pandemic response test menu that alleviated the pressure on oncology testing volumes. Furthermore, we continued to expand our global Idylla™ ecosystem, attracted new partners and made significant operational progress on our path towards continued growth,” states Herman Verrelst, CEO of Biocartis.
Today, Biocartis along with its pharma partners is focused on enabling seamless access to treatment by ensuring companion diagnostic testing readiness in the relevant markets. The experienced project managers, highly qualified scientists, and manufacturing, quality, and regulatory personnel, along with the commercial team, are always ready to help the clients accelerate all aspects of their co-development efforts from research through clinical and commercial phases.